Analyst Corentin Marty from TP ICAP MIDCAP reiterated a Buy rating on PharmaNutra SpA and keeping the price target at €74.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Corentin Marty has given his Buy rating due to a combination of factors linked to PharmaNutra’s growth momentum and valuation profile. He highlights the continuing strength of SiderAL in the US, where sales on Amazon have accelerated sharply and the product has climbed steadily up the rankings of best-selling iron supplements, indicating sustained traction with consumers. The visible increase in purchase volumes on the platform suggests that the current annualized revenue pace in the US is already materially higher than in 2025, pointing to a strong start to 2026.
Marty also underlines that PharmaNutra remains one of his preferred names for the first half of 2026, reflecting confidence in the company’s growth prospects. Despite a significant rise in the share price over recent months, he judges that the stock still offers notable upside, as the earnings outlook remains solid and market valuation multiples are below their historical norms. In particular, the shares trade at a sizeable discount to their five-year average metrics, which, in his view, provides an attractive entry point for investors. Consequently, he reiterates a Buy recommendation and maintains his existing target price, seeing room for further appreciation.
In another report released yesterday, TipRanks – OpenAI also upgraded the stock to a Buy with a €71.00 price target.